RAD receives IND approval from US FDA for Betabart (RV-01)

by admin July 28, 2025

July 28, 2025

Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)

Download the PDF here.

This post appeared first on investingnews.com

0

Facebook Twitter Google +Pinterest

Top 5 Canadian Mining Stocks This Week: Onyx...

NevGold

Ted Butler: Silver’s Moment is Here, Time for...

Lithium Universe LtdInterview with Executive Chairman

Rare Earths Firm MP Materials to Get US$400...

Osisko Metals Infill and Expansion Drilling Intersects New...

Charbone Hydrogene annonce une mise-a-jour sur les reglements...

Fortune Minerals Announces Results of Annual Meeting of...

Nuvau’s Gold-Focused Exploration Program Underway at Matagami

Extensive Greenland Lithium Exploration Campaign Launched by Brunswick...

Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Latest

Anteros Metals Initiates Channel Sampling at Havens Steady Following Grant Confirmation and...
Allied Critical Metals Launches Allied USA to Expand Tungsten Import and Distribution Operations, Lists on OTCQB, and Receives DTC Eligibility
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart
Crypto Market Update: Americans Still Uninterested in Crypto Despite Institutional Support
Obama issues rare statement on foreign policy issue

Categories

Business (70)
Investing (521)
Politics (700)
World (262)

About us
Contacts
Privacy Policy
Terms & Conditions
Email Whitelisting

Disclaimer: toppricemarket.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Back To Top

RAD receives IND approval from US FDA for Betabart (RV-01)

Maiden Drill Program Commences at Oasis Uranium Project

Agreement to Develop New Expandable Graphite Facility

You may also like